Pharma DECODED
Previous edition: 16 May 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Allucent receives grant for decentralised Covid-19 vaccine trial
The company received the award to conduct a trial assessing correlates of protection following Covid-19 vaccination.
Allucent has received a $25.5m Biomedical Advanced Research and Development Authority (BARDA)-funded grant to support a Covid-19 vaccine decentralised clinical trial.
The award granted through the Rapid Response Partnership Vehicle (RRPV) Consortium is part of Project NextGen.
The trial will focus on establishing correlates of protection (CoPs) in a geographically diverse population to understand the range of immunologic responses to Covid-19 and its vaccines.
By leveraging its expertise in DCTs, Allucent aims to facilitate broader participation and reduce the burdens typically associated with clinical trial involvement.
The company will initiate a 4,000-participant decentralised Phase IV observational study using the project award.
The study will evaluate CoPs following vaccination with a US Food and Drug Administration (FDA)-approved or authorised vaccine.
Allucent’s customised DCT model will be used in the trial to enhance the participant experience.
The trial will explore the feasibility of remote, self-collected specimens for CoP analysis and will incorporate wearable devices to potentially predict Covid-19 infections.
The insights gained from the data collected will contribute to the ongoing efforts to combat the Covid-19 pandemic.
Allucent chairman and CEO Mark Goldberg said: “We are proud to apply our decentralised trial expertise as a partner to BARDA on this initiative.
“The continuing emergence of new variants and subvariants underscores the need for ongoing optimisation of Covid-19 vaccines to ensure their effectiveness in combating the virus. This study is a step forward in addressing the evolving challenges posed by Covid-19 and mitigating their impact on public health.”
Latest news
KRAS inhibitors: The next frontier beckons
There has been several developments in the KRAS inhibitor space, shaping the KRAS inhibitors of the future.
FDA approves Bristol Myers Squibb's Breyanzi for follicular lymphoma
The approval is based on results from the open-label, global, multi-centre, single-arm Phase II TRANSCEND FL clinical trial.
Takeda's dengue vaccine obtains WHO prequalification
The TAK-003 vaccine targets all four virus serotypes.
FDA rejects label expansion for Dynavax's hepatitis B vaccine
The US agency rejected the expanded use of Dynavax’s vaccine for adults on haemodialysis, citing insufficient efficacy and safety data.
Tracking the opioid lawsuit settlements amidst calls for oversight
The US National Opioid Settlement is distributing more than $54 billion to communities grappling with the opioid crisis.
Vanda Pharmaceuticals reports positive data from motion sickness trial
In the trial, only 10.4% and 18.3% of the subjects reported vomiting on the 170mg and 85mg doses, respectively.
Moleculin begins NIH-funded Phase II glioblastoma treatment trial
The primary goal of the study is to measure progression-free survival.
In our previous edition
Pharma Decoded
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
15 May 2024
Pharma Decoded
Sanofi to make €1bn biomanufacturing investment in France
14 May 2024
Pharma Decoded
RAPT terminates Phase II trials for lead candidate following clinical hold
13 May 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Banking & Payments
Medical Devices
Oil & Gas
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer